Bacillus Calmette-Guerin Failure in Patients with Non-Muscle-invasive Urothelial Carcinoma of the Bladder May Be Due to the Urologist's Failure to Detect Urothelial Carcinoma of the Upper Urinary Tract and Urethra

被引:24
作者
Giannarini, Gianluca [1 ]
Birkhaeuser, Frederic D. [1 ]
Recker, Franz [2 ]
Thalmann, George N. [1 ]
Studer, Urs E. [1 ]
机构
[1] Univ Bern, Dept Urol, Inselspital, CH-3010 Bern, Switzerland
[2] Kantonsspital Aarau, Dept Urol, Aarau, Switzerland
关键词
Bladder neoplasms; Urothelial carcinoma; Carcinoma in situ; Bacillus Calmette-Guerin; Upper urinary tract; Cytology; Follow-up studies; RADICAL CYSTECTOMY; THERAPY; CANCER;
D O I
10.1016/j.eururo.2013.09.049
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: Various reasons exist for so-called bacillus Calmette-Guerin (BCG) failure in patients with non-muscle-invasive urothelial bladder carcinoma (NMIBC). Objective: To explore whether urothelial carcinoma of the upper urinary tract (UUT) and/or prostatic urethra may be a cause for BCG failure. Design, setting, and participants: Retrospective analysis of 110 patients with high-risk NMIBC repeatedly treated with intravesical BCG, diagnosed with disease recurrence, and followed for a median time of 9.1 yr. Intervention: Two or more intravesical BCG induction courses without maintenance. Outcome measurements and statistical analysis: Primary outcome was pattern of disease recurrence (BCG failure) within the urinary tract categorised into UUT and/or urethral carcinoma (with or without intravesical recurrence), and intravesical recurrence alone. Secondary outcome was survival. Predictors of UUT and/or urethral carcinoma and the effect of pattern of disease recurrence on cancer-specific survival were assessed with multivariable Cox regression analysis adjusting for multiple clinical and tumour characteristics. Results and limitations: Of the 110 patients, 57 (52%) had UUT and/or urethral carcinoma (with or without intravesical recurrence), and 53 (48%) had intravesical recurrence alone. In patientswithUUT and/or urethral carcinoma, bladder carcinoma in situ (Tis) before the first and second BCG course was present in 42 of 57 (74%) and 47 of 57 (82%) patients, respectively. On multivariable analysis, bladder Tis before the first and/or second BCG course was the only independent predictor of UUT and/or urethral carcinoma. Of the 110 patients, 69 (63%) were alive at last follow-up visit, 18 (16%) had died due to metastatic urothelial carcinoma, and 23 (21%) had died of other causes. Pattern of disease recurrence within the urinary tractwas notan independent predictor of cancer-specific survival. Main study limitations were retrospective design and limited power for survival analysis. Conclusions: In our patients with high-risk NMIBC failing after two or more courses of intravesical BCG, UUT and/or urethral carcinoma was detected in >50% of the cases during follow-up. The vastmajority of these patientshadbladder Tisbefore the firstand/or second BCG course. In patients experiencing the so-called BCG failure, a diagnostic work-up of UUT and prostatic urethra should always be performed to exclude urothelial carcinoma before additional intravesical therapy or even a radical cystectomy is considered. (C) 2013 Published by Elsevier B.V. on behalf of European Association of Urology.
引用
收藏
页码:825 / 831
页数:7
相关论文
共 50 条
[21]   Swedish National Guidelines on Urothelial Carcinoma: 2021 update on non-muscle invasive bladder cancer and upper tract urothelial carcinoma [J].
Liedberg, Fredrik ;
Kjellstrom, Sofia ;
Lind, Anna-Karin ;
Sherif, Amir ;
Soderkvist, Karin ;
Falkman, Karin ;
Thulin, Helena ;
Aljabery, Firas ;
Papantonio, Dimitrious ;
Strock, Viveka ;
Ofverholm, Elisabeth ;
Jerlstrom, Tomas ;
Sandzen, Johan ;
Verbiene, Ingrida ;
Ullen, Anders .
SCANDINAVIAN JOURNAL OF UROLOGY, 2022, 56 (02) :137-146
[22]   Efficacy and toxicity of intravesical Bacillus Calmette-Guerin therapy in elderly patients with non-muscle-invasive bladder cancer [J].
Matsuoka, Yuki ;
Taoka, Rikiya ;
Kohashiguchi, Kana ;
Tohi, Yoichiro ;
Miyauchi, Yasuyuki ;
Kato, Takuma ;
Tsunemori, Hiroyuki ;
Ueda, Nobufumi ;
Sugimoto, Mikio .
CURRENT UROLOGY, 2021, 15 (01) :16-21
[23]   Intrarenal bacillus Calmette-Guerin therapy for carcinoma in situ of the upper urinary tract:: long-term follow-up and natural course in cases of failure [J].
Okubo, K ;
Ichioka, K ;
Terada, N ;
Matsuta, Y ;
Yoshimura, K ;
Arai, Y .
BJU INTERNATIONAL, 2001, 88 (04) :343-347
[24]   Gemcitabine Versus Bacille Calmette-Guerin After Initial Bacille Calmette-Guerin Failure in Non-Muscle-Invasive Bladder Cancer A Multicenter Prospective Randomized Trial [J].
Di Lorenzo, Giuseppe ;
Perdona, Sisto ;
Damiano, Rocco ;
Faiella, Adriana ;
Cantiello, Francesco ;
Pignata, Sandro ;
Ascierto, Paolo ;
Simeone, Ester ;
De Sio, Marco ;
Autorino, Riccardo .
CANCER, 2010, 116 (08) :1893-1900
[25]   Real-world treatment patterns and oncological outcomes in early relapse and refractory disease after bacillus Calmette-Guerin failure in non-muscle-invasive bladder cancer [J].
Murakami, Yasukiyo ;
Matsumoto, Kazumasa ;
Miyake, Makito ;
Amano, Noriyuki ;
Shimura, Soichiro ;
Nishimura, Nobutaka ;
Iida, Kota ;
Matsushita, Yuto ;
Abe, Takashige ;
Yamada, Takeshi ;
Uemura, Motohide ;
Matsui, Yoshiyuki ;
Taoka, Rikiya ;
Kojima, Takahiro ;
Kobayashi, Takashi ;
Nishiyama, Naotaka ;
Kitamura, Hiroshi ;
Nishiyama, Hiroyuki ;
Fujimoto, Kiyohide ;
Iwamura, Masatsugu .
INTERNATIONAL JOURNAL OF UROLOGY, 2022, 29 (10) :1195-1203
[26]   Impact of carcinoma in situ on the outcome of intravesical Bacillus Calmette-Guerin therapy for non-muscle-invasive bladder cancer: a comparative analysis of large real-world data [J].
Tomida, Ryotaro ;
Miyake, Makito ;
Minato, Ryoei ;
Sawada, Yuichiro ;
Matsumura, Masafumi ;
Iida, Kota ;
Hori, Shunta ;
Fukui, Shinji ;
Ohyama, Chikara ;
Miyake, Hideaki ;
Hongo, Fumiya ;
Taoka, Rikiya ;
Kobayashi, Takashi ;
Kojima, Takahiro ;
Matsui, Yoshiyuki ;
Nishiyama, Naotaka ;
Kitamura, Hiroshi ;
Nishiyama, Hiroyuki ;
Fujimoto, Kiyohide ;
Hashine, Katsuyoshi .
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2022, 27 (05) :958-968
[27]   Optimal Timing of Chemotherapy and Surgery in Patients with Muscle-Invasive Bladder Cancer and Upper Urinary Tract Urothelial Carcinoma [J].
Tabayoyong, William ;
Li, Roger ;
Gao, Jianjun ;
Kamat, Ashish .
UROLOGIC CLINICS OF NORTH AMERICA, 2018, 45 (02) :155-+
[28]   Presence of Concomitant Non-muscle-invasive Bladder Cancer in Chinese Patients with Upper Tract Urothelial Carcinoma: Risk Factors, Characteristics, and Predictive Value [J].
Fang, Dong ;
Zhang, Lei ;
Li, Xuesong ;
Yu, Wei ;
Singla, Nirmish ;
Zhao, Guangzhi ;
Xiong, Gengyan ;
Song, Yi ;
He, Qun ;
He, Zhisong ;
Zhou, Liqun .
ANNALS OF SURGICAL ONCOLOGY, 2015, 22 (08) :2789-2798
[29]   Presence of Concomitant Non-muscle-invasive Bladder Cancer in Chinese Patients with Upper Tract Urothelial Carcinoma: Risk Factors, Characteristics, and Predictive Value [J].
Dong Fang ;
Lei Zhang ;
Xuesong Li ;
Wei Yu ;
Nirmish Singla ;
Guangzhi Zhao ;
Gengyan Xiong ;
Yi Song ;
Qun He ;
Zhisong He ;
Liqun Zhou .
Annals of Surgical Oncology, 2015, 22 :2789-2798
[30]   Intravesical Bacillus Calmette-Guerin Versus Combination of Epirubicin and Interferon-α2a in Reducing Recurrence of Non-Muscle-invasive Bladder Carcinoma: FinnBladder-6 Study [J].
Marttila, Timo ;
Jarvinen, Riikka ;
Liukkonen, Tapani ;
Rintala, Erkki ;
Bostrom, Peter ;
Seppanen, Marjo ;
Tammela, Teuvo ;
Hellstrom, Pekka ;
Aaltomaa, Sirpa ;
Leskinen, Markku ;
Raitanen, Mika ;
Kaasinen, Eero .
EUROPEAN UROLOGY, 2016, 70 (02) :341-347